213 related articles for article (PubMed ID: 22524291)
21. Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5.
Bierbaum G; Szekat C; Josten M; Heidrich C; Kempter C; Jung G; Sahl HG
Appl Environ Microbiol; 1996 Feb; 62(2):385-92. PubMed ID: 8593044
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics.
Kakkar N; Perez JG; Liu WR; Jewett MC; van der Donk WA
ACS Chem Biol; 2018 Apr; 13(4):951-957. PubMed ID: 29439566
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in synthetic analogues of lantibiotics: What can we learn from these?
Tabor AB
Bioorg Chem; 2014 Aug; 55():39-50. PubMed ID: 24877613
[TBL] [Abstract][Full Text] [Related]
24. Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production.
Ongey EL; Neubauer P
Microb Cell Fact; 2016 Jun; 15():97. PubMed ID: 27267232
[TBL] [Abstract][Full Text] [Related]
25. Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation.
Knerr PJ; Oman TJ; Garcia De Gonzalo CV; Lupoli TJ; Walker S; van der Donk WA
ACS Chem Biol; 2012 Nov; 7(11):1791-5. PubMed ID: 22920239
[TBL] [Abstract][Full Text] [Related]
26. Cacaoidin, First Member of the New Lanthidin RiPP Family.
Ortiz-López FJ; Carretero-Molina D; Sánchez-Hidalgo M; Martín J; González I; Román-Hurtado F; de la Cruz M; García-Fernández S; Reyes F; Deisinger JP; Müller A; Schneider T; Genilloud O
Angew Chem Int Ed Engl; 2020 Jul; 59(31):12654-12658. PubMed ID: 32407589
[TBL] [Abstract][Full Text] [Related]
27. Lantibiotics: mode of action, biosynthesis and bioengineering.
Bierbaum G; Sahl HG
Curr Pharm Biotechnol; 2009 Jan; 10(1):2-18. PubMed ID: 19149587
[TBL] [Abstract][Full Text] [Related]
28. Dissecting structural and functional diversity of the lantibiotic mersacidin.
Appleyard AN; Choi S; Read DM; Lightfoot A; Boakes S; Hoffmann A; Chopra I; Bierbaum G; Rudd BA; Dawson MJ; Cortes J
Chem Biol; 2009 May; 16(5):490-8. PubMed ID: 19477413
[TBL] [Abstract][Full Text] [Related]
29. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp.
Castiglione F; Cavaletti L; Losi D; Lazzarini A; Carrano L; Feroggio M; Ciciliato I; Corti E; Candiani G; Marinelli F; Selva E
Biochemistry; 2007 May; 46(20):5884-95. PubMed ID: 17469849
[TBL] [Abstract][Full Text] [Related]
30. Multipronged approach for engineering novel peptide analogues of existing lantibiotics.
Escano J; Smith L
Expert Opin Drug Discov; 2015; 10(8):857-70. PubMed ID: 26004576
[TBL] [Abstract][Full Text] [Related]
31. The structure of the lantibiotic lacticin 481 produced by Lactococcus lactis: location of the thioether bridges.
van den Hooven HW; Lagerwerf FM; Heerma W; Haverkamp J; Piard JC; Hilbers CW; Siezen RJ; Kuipers OP; Rollema HS
FEBS Lett; 1996 Aug; 391(3):317-22. PubMed ID: 8764998
[TBL] [Abstract][Full Text] [Related]
32. Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.
Geng M; Smith L
Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29776930
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and evaluation of antimicrobial activity of N-terminal modified Leucocin A analogues.
Bodapati KC; Soudy R; Etayash H; Stiles M; Kaur K
Bioorg Med Chem; 2013 Jul; 21(13):3715-22. PubMed ID: 23673216
[TBL] [Abstract][Full Text] [Related]
34. Epidermin and gallidermin: Staphylococcal lantibiotics.
Götz F; Perconti S; Popella P; Werner R; Schlag M
Int J Med Microbiol; 2014 Jan; 304(1):63-71. PubMed ID: 24119540
[TBL] [Abstract][Full Text] [Related]
35. Brominated Variant of the Lantibiotic NAI-107 with Enhanced Antibacterial Potency.
Cruz JC; Iorio M; Monciardini P; Simone M; Brunati C; Gaspari E; Maffioli SI; Wellington E; Sosio M; Donadio S
J Nat Prod; 2015 Nov; 78(11):2642-7. PubMed ID: 26512731
[TBL] [Abstract][Full Text] [Related]
36. Investigating the importance of charged residues in lantibiotics.
Suda S; Hill C; Cotter PD; Ross RP
Bioeng Bugs; 2010; 1(5):345-51. PubMed ID: 21326835
[TBL] [Abstract][Full Text] [Related]
37. Lantibiotics: structure, biosynthesis and mode of action.
McAuliffe O; Ross RP; Hill C
FEMS Microbiol Rev; 2001 May; 25(3):285-308. PubMed ID: 11348686
[TBL] [Abstract][Full Text] [Related]
38. Type AII lantibiotic bovicin HJ50 with a rare disulfide bond: structure, structure-activity relationships and mode of action.
Zhang J; Feng Y; Teng K; Lin Y; Gao Y; Wang J; Zhong J
Biochem J; 2014 Aug; 461(3):497-508. PubMed ID: 24814218
[TBL] [Abstract][Full Text] [Related]
39. Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides.
Basi-Chipalu S; Dischinger J; Josten M; Szekat C; Zweynert A; Sahl HG; Bierbaum G
Appl Environ Microbiol; 2015 May; 81(10):3419-29. PubMed ID: 25769830
[TBL] [Abstract][Full Text] [Related]
40. A concise stereoselective synthesis of orthogonally protected lanthionine and beta-methyllanthionine.
Cobb SL; Vederas JC
Org Biomol Chem; 2007 Apr; 5(7):1031-8. PubMed ID: 17377656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
